Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Disease-Site Specific Peer Review Implementation: From Chart Rounds to the Treatment Couch.

Advances in radiation oncology·2026

Same author

PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder Cancer After Bladder-Sparing Trimodality Therapy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Advancing radiation oncology care in Ukraine during the war: impact of international observerships on professional development and clinical practice.

Frontiers in oncology·2026

Same author

Prospective operational feasibility, safety, and workflow of magnetic resonance-guided tracking technology for interstitial gynecologic brachytherapy.

Brachytherapy·2026

Same author

PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder Cancer After Bladder-Sparing Trimodality Therapy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Parallel course of calcinosis and cancer in a patient with anti-NXP2-positive dermatomyositis: A case report.

Modern rheumatology case reports·2026

Search research articles

Related Experiment Video

Updated: May 10, 2026

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Concurrent chemoradiation for vaginal cancer.

David T Miyamoto¹, Akila N Viswanathan

¹Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, United States of America.

|June 14, 2013

Summary

Adding chemotherapy to radiation therapy significantly improves survival outcomes for vaginal cancer patients. Concurrent chemoradiation therapy (CRT) demonstrated superior overall survival and disease-free survival compared to radiation therapy alone.

Area of Science:

Gynecologic Oncology
Radiation Oncology
Medical Oncology

Background:

Outcomes for primary vaginal cancer remain suboptimal.
The role of chemotherapy in conjunction with radiation therapy for vaginal cancer is not well-established.

Purpose of the Study:

To evaluate the impact of concurrent chemoradiation therapy (CRT) versus radiation therapy (RT) alone on clinical outcomes in patients with primary vaginal cancer.

Main Methods:

A retrospective review of 71 patients with primary vaginal cancer treated with definitive RT with or without concurrent chemotherapy.
Survival rates (OS, DFS) were analyzed using Kaplan-Meier and Cox regression.

Main Results:

Concurrent chemoradiation therapy (CRT) was associated with significantly improved 3-year overall survival (79% vs. 56%) and disease-free survival (73% vs. 43%) compared to RT alone.

More Related Videos

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Related Experiment Videos

Last Updated: May 10, 2026

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Relapse rates were significantly lower in the CRT group (15% vs. 45%).

Concurrent chemotherapy was a significant predictor of improved DFS on multivariate analysis.

Conclusions:

Vaginal cancer is associated with poor prognoses, underscoring the need for effective treatment strategies.
Adequate radiation dosing is critical for curative intent in vaginal cancer management.
Concurrent chemotherapy should be strongly considered for patients diagnosed with vaginal cancer to improve outcomes.